Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m(2): Subgroup Analysis of the Randomized CREDENCE Trial

BACKGROUND AND OBJECTIVES: The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial demonstrated that the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduced the risk of kidney failure and cardiovascular events in participant...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin J Am Soc Nephrol
Main Authors: Bakris, George, Oshima, Megumi, Mahaffey, Kenneth W., Agarwal, Rajiv, Cannon, Christopher P., Capuano, George, Charytan, David M., de Zeeuw, Dick, Edwards, Robert, Greene, Tom, Heerspink, Hiddo J.L., Levin, Adeera, Neal, Bruce, Oh, Richard, Pollock, Carol, Rosenthal, Norman, Wheeler, David C., Zhang, Hong, Zinman, Bernard, Jardine, Meg J., Perkovic, Vlado
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769025/
https://ncbi.nlm.nih.gov/pubmed/33214158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.10140620
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados